麻豆传媒

Few responses with or without guidance in small first step for "personalized" treatment

Local control in 91% of cases at 1 year in small prospective trial

One first-line regimen led to worse OS, while another offers an additional option

High response rate with oncolytic virus plus immunotherapy in cutaneous lesions

SCOTTSDALE, Ariz. -- Chemoradiation plus the targeted agent zalutumumab failed to improve disease control or survival in patients with squamous cell head and neck cancer, a finding that leads this roundup of news from the Multidisciplinary Head and Neck Cancer Symposium.

PHOENIX -- Patients with head and neck cancer had substantial sparing of oral mucosa when they used custom-made dental stents to shield normal tissue from radiation therapy, data from a small clinical series showed.

PHOENIX -- Osteoradionecrosis of the jaw occurred more than twice as often in patients treated for oral cancer as reported in the literature, according to a population-based study.